XC8 in the Treatment of Patients With Bronchial Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 20, 2016

Primary Completion Date

September 27, 2017

Study Completion Date

September 27, 2017

Conditions
Bronchial Asthma
Interventions
DRUG

XC8 Oral Tablet

1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.

DRUG

Placebo Oral Tablet

Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.

Trial Locations (12)

19510

"Saint Petersburg State Monetary Healthcare Institution Nicolaevskiy Hospital", Saint Petersburg

105077

"Pulmonology Research Institute FMBA of Russia", Moscow

107564

Central Research Institute for Tuberculosis at Russian Medical Sciences, Moscow

121552

"Moscow State Medical-Dentist University n.a. A.I. Evdokimov on basis of SMHI City Hospital № 62, branch 5", Moscow

123995

Russian Medical Academy of postgraduate education of Ministry of Healthcare on basis of city's Clinical Hospital № 52, Moscow

150003

"State autonomous healthcare institution of Yaroslavl Region Сlinical hospital for emergency medical care n. a. N.V. Solovyov", Yaroslavl

194291

"State Budgetary Institution of Healthcare Leningrad region Clinical Hospital", Saint Petersburg

196084

"Medical Researches Institute LLC", Saint Petersburg

214019

"Federal State Budgetary Educational Institution of the Higher Education Smolensk State Medical", Smolensk

350007

"Allergy and Immunology Center LLC", Krasnodar

390005

Ryazan State Medical University, Ryazan

410053

"State Healthcare Institution Regional Clinical Hospital", Saratov

All Listed Sponsors
collaborator

EURRUS Biotech GmbH

INDUSTRY

lead

PHARMENTERPRISES LLC

INDUSTRY

NCT03450434 - XC8 in the Treatment of Patients With Bronchial Asthma | Biotech Hunter | Biotech Hunter